Aqueous suspension agent containing glucocorticosteroid nanoparticles
An aqueous suspension containing as an active component a glucocorticosteroid compound is described. The aqueous suspension contains nanoparticles of a glucocorticosteroid compound and a dispersion stabilizer. The nanoparticles have a mean particle diameter of 300 nm or less and a D90 particle diameter of 450 nm or less. The pharmaceutical compositions containing the aqueous suspension are for parenteral administrations, injections, eye drops or ear drops. More specifically the aqueous suspensions containing glucocorticosteroid nanoparticles are used as an eye drop for treating or preventing inflammatory diseases of the eye or an ear drop for treating or preventing inflammatory diseases of the ear.
1. An aqueous suspension comprising:
nanoparticles of a glucocorticosteroid compound;
a physiologically acceptable salt;
glycerin;
hydrogenated soybean lecithin; and
anhydrous citric acid;
wherein a mean particle diameter of the nanoparticles is 300 nm or less and a D90 particle diameter of the nanoparticles is 450 nm or less.
2. An aqueous suspension comprising nanoparticles of a glucocorticosteroid compound, wherein a mean particle diameter of the nanoparticles is 300 nm or less and a D90 particle diameter of the nanoparticles is 450 nm or less, and the nanoparticles are produced by mixing the glucocorticosteroid compound, a physiologically acceptable salt, glycerin, hydrogenated soybean lecithin and anhydrous citric acid.
3. The aqueous suspension of claim 1 , wherein the glucocorticosteroid compound is one or more substances selected from the group consisting of clobetasol propionate, diflorasone diacetate, dexamethasone propionate, difluprednate, mometasone furoate, diflucortolone valerate, betamethasone butyrate propionate, fluocinonide, hydrocortisone butyrate propionate, beclomethasone dipropionate, deprodone propionate, betamethasone valerate, dexamethasone valerate, prednisolone valerate acetate, fluocinolone acetonide, hydrocortisone butyrate, clobetasone butyrate, alclometasone dipropionate, triamcinolone acetonide, flumethasone pivalate, prednisolone and hydrocortisone.
4. The aqueous suspension of claim 1 , further comprising a dispersion stabilizer.
5. The aqueous suspension of claim 4 , wherein the dispersion stabilizer is polyoxyethylene polyoxypropylene glycol and/or polyvinyl alcohol.
6. The aqueous suspension of claim 1 , further comprising a viscosity modifier.
7. The aqueous suspension of claim 6 , wherein the viscosity modifier is one or more substances selected from the group consisting of methyl cellulose, hydroxypropyl methylcellulose and polyvinyl alcohol.
8. The aqueous suspension of claim 6 , comprising 1 to 10 mg/mL of the viscosity modifier.
9. A pharmaceutical composition comprising the aqueous suspension of claim 1 .
10. The pharmaceutical composition of claim 9 , for parenteral administration.
11. The pharmaceutical composition of claim 10 , which is for an injection or for a topical preparation.
12. The pharmaceutical composition of claim 11 , which is for a topical preparation for an eye, an ear, a nose or a lung.
13. The pharmaceutical composition of claim 12 , which is an eye drop, an ear drop, a nose drop, or an inhaler.
14. A kit for preparing the pharmaceutical composition of claim 9 , comprising nanoparticles of a glucocorticosteroid compound.
15. A method for manufacturing the pharmaceutical composition of claim 9 , comprising mixing the glucocorticosteroid compound, the physiologically acceptable salt, the glycerin, the hydrogenated soybean lecithin and the anhydrous citric acid.
16. The method for manufacturing of claim 15 , comprising mixing the glucocorticosteroid compound, the physiologically acceptable salt, the glycerin, the anhydrous citric acid the hydrogenated soybean lecithin, a physiologically acceptable polyol and/or water, and a dispersion stabilizer.